This educational program consists of three presentations on integrating icosapent ethyl in clinical practice.

This course consists of the following:

• Recent clinical insights into icosapent ethyl - Prof. Deepak Bhatt, MD - Boston, MA, USA
• A continuum of multifactorial benefits of icosapent ethyl? - Prof. Magnus Bäck, MD, PhD - Stockholm, Sweden
• 11 Practical implications of REDUCE-IT - Prof. Subodh Verma, MD, PhD - Toronto, ON, Canada

How to obtain your CME certificate

• Watch the three lectures and answer the pre- and post-test questions
• Fill in the evaluation questions
• Download CME Certificate (if your score >70%)

After watching these three videos, the learner should be able to:

• Describe the study design of the REDUCE-IT trial and its main results
• Name 3 potential mechanisms resulting in benefits of icosapent ethyl
• Recall at least 6 clinical implications of the REDUCE-IT trial

Expert faculty

• Prof. Deepak Bhatt, MD - Boston, MA, USA
• Prof. Magnus Bäck, MD, PhD - Stockholm, Sweden
• Prof. Subodh Verma, MD, PhD - Toronto, ON, Canada

Target audience

This educational activity is designed for all healthcare professionals with an interest in management of patients with elevated CV risk.

CME accreditation

This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Amarin.

Questions

For questions regarding this activity, please contact us at info@pace-cme.org.